-
Neutralizing antibody (NAbs) positivity does not reduce the efficacy of interferon beta-1b (IFNbeta-1b) treatment, according to results of a substudy analysis of patients with a first event suggestive of multiple sclerosis (MS) in a multicentre, randomize
-
In the past few years, it has been shown that many drugs are not equally effective for every patient, and this variability is due, at least in part, to genetic differences.
-
The number of events (relapses) was insufficient to establish a statistically significant difference between the two products, despite a trend advantage for Rebif
-
The BENEFIT study (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment), sponsored by Bayer HealthCare, compared Betaseron treatment initiated after a first clinical event with delayed treatment.
-
"We have shown for the first time that immediate treatment after a first clinical demyelinating event suggestive of MS can reduce the early neurological damage, which may ultimately delay the development of the debilitating sequelae that characterize adv
-
This month a UCLA researcher begins a widespread clinical trial of the female sex hormone estriol, produced during pregnancy, which she’s shown sharply reduces the symptoms of multiple sclerosis.
-
Patients given daclizumab every two weeks had a significantly reduced lesions at week 24 compared with those in the placebo group.
-
In clinical studies for the lead indication of multiple sclerosis (MS), Revimmune improves function in most patients and stops progression in over 90% of cases refractory to standard therapies;
-
BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), today announced that it has initiated MAESTRO-02, the open-label follow-on portion to its MAESTRO-01 pivotal phase II/III clinical trial of MBP8298
-
The new peptides have been found to be more effective than Copaxone® in in-vitro and in-vivo assays, as well as in animal disease models of MS.
-
The TERMS (Tovaxin for Early Relapsing Multiple Sclerosis) study is testing Tovaxin, an autologous T-Cell vaccination in patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis
-
Merck Serono announced today that it has begun the ONWARD (Oral Cladribine Added ON To Rebif New Formulation in Patients With Active Relapsing Disease) Phase II study.
-
Merck Serono announced today that patient enrollment has been completed in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III pivotal clinical trial evaluating the efficacy and safety
-
Researchers at the Roslin Institute in Edinburgh have genetically engineered chickens that could one day produce medicines to fight diseases like cancer and multiple sclerosis in their eggs.
-
The MS Society is 'bitterly disappointed' after the Scottish Medicines Consortium (SMC) advised health professionals not to prescribe Tysabri - the only drug licensed for multiple sclerosis (MS) that has shown significant promise in slowing the progress
